Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel

References

• Stock W, La M, Sanford B,. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood 2008;112:1646–1654.
   PubMed Web of Science ®Google Scholar
• Boissel N, Auclerc MF, Lheritier V, . Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol 2003;21:774–780.
   PubMed Web of Science ®Google Scholar
• de Bont JM, Holt B, Dekker AW, van der Does-van den Berg A, Sonneveld P, Pieters R. Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia 2004;18: 2032–2035.
   PubMed Web of Science ®Google Scholar
• de Bont JM, van der Holt B, Dekker AW, van der Does-van den Berg A, Sonneveld P, Pieters R. Adolescents with acute lymphatic leukaemia achieve significantly better results when treated following Dutch paediatric oncology protocols than with adult protocols. Ned Tijdschr Geneeskd 2005;149:400–406.
   PubMedGoogle Scholar
• Schroeder H, Kjeldahl M, Boeson AM, . Prognosis of ALL in 10-20 year old patients in Denmark 1992-2001. Pediatr Blood Cancer 2005;45:578 [Abstract].
   Google Scholar
• Testi A. Difference in outcome of adolescents (14–17 years) with acute lymphoblastic leukaemia (ALL) enrolled in the Italian pediatric (AIEOP) an adult (GIMEMA) multicenter treatment protocols. J Clin Oncol 2006;24(18 Suppl.): Abstract 9024.
   Web of Science ®Google Scholar
• Ramanujachar R, Richards S, Hann I, . Adolescents with acute lymphoblastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials. Pediatr Blood Cancer 2007;48:254–261.
   PubMed Web of Science ®Google Scholar
• Ramanujachar R, Richards S, Hann I, Webb D. Adolescents with acute lymphoblastic leukaemia: emerging from the shadow of paediatric and adult treatment protocols. Pediatr Blood Cancer 2006;43:748–756.
   Web of Science ®Google Scholar
• Barry E, DeAngelo DJ, Neuberg D, . Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. J Clin Oncol 2007;25:813–819.
   PubMed Web of Science ®Google Scholar
• Sallan SE, Gelber RD, Kimball V, Donnelly M, Cohen HJ. More is better! Update of Dana-Farber Cancer Institute/Children's Hospital childhood acute lymphoblastic leukemia trials. Haematol Blood Transfus 1990;33:459–466.
   PubMedGoogle Scholar
• Amylon MD, Shuster J, Pullen J. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia: a Pediatric Oncology Group Study. Blood 2000;96:335–342.
   Google Scholar
• Raetz EA, Salzer WL. Tolerability and efficacy of L-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia. J Pediatr Hemat Oncol 2010;32:554–563.
   PubMed Web of Science ®Google Scholar
• Asselin BL, Kreissman S, Coppola DJ, Bernal SD, Leavitt PR, Gelber RD, Sallan SE, Cohen HJ. Prognostic significance of early response to a single dose of asparaginase in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 1999;21(1):6–12.
   PubMed Web of Science ®Google Scholar
• Silverman L, Gelber RD, Dalton VK, . Improved outcome for children with acute lymphoblastic leukemia:results of Dana-Farber consortium protocol 91-01. Blood 2001:97;1211–1218.
   PubMed Web of Science ®Google Scholar
• Nachman JB, La MK, Hunger SP, . Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the Children's Oncology Group. J Clin Oncol 2009;27:5189–5194.
   PubMed Web of Science ®Google Scholar
• Wetzler M, Sanford BL, Kurtzburg J, . Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511. Blood 2007;109:4164–4167.
   PubMed Web of Science ®Google Scholar
• Huguet F, Leguay T, Raffoux E, . Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol 2009;27:911–918.
   PubMed Web of Science ®Google Scholar
• Goekbuget N, Baumann A, Beck J, . PEG-asparaginase in adult acute lymphoblastic leukemia: efficacy and feasibility analysis with increasing dose levels. Blood 2008;112(Suppl. 1): Abstract 302.
   Google Scholar
• DeAngelo DJ. The treatment of adolescents and young adults with acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2005:123–130.
   PubMedGoogle Scholar
• DeAngelo DJ, Stone RM. New agents for the treatment of patients with acute lymphoblastic leukemia. Curr Hematol Malig Rep 2008;3:135–143.
   PubMedGoogle Scholar
• Aguayo A, Cortes J, Thomas D, . Combination therapy with methotrexate, vincristine, polyethylene-glycol conjugated-asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia. Cancer 1999;86:1203–1209.
   PubMed Web of Science ®Google Scholar
• Rosen O, Muller HJ, Gokbuget N, . Pegylated asparaginase in combination with high-dose methotrexate for consolidation in adult acute lymphoblastic leukaemia in first remission: a pilot study. Br J Haematol 2003;123:836–841.
   PubMed Web of Science ®Google Scholar
• Storring J, Minden M, Kao S, . Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen. Br J Haematol 2009;146:76–85.
   PubMed Web of Science ®Google Scholar
• Oettgen HF, Stephenson PA, Schwartz MK, . Toxicity of E.coli l-asparaginase in man. Cancer 1970;25:253–278.
   PubMedGoogle Scholar
• Dinndorf PA, Gootenberg J, Cohen MH, Keegan P, Pazdur R. FDA drug approval summary: pegaspargase (Oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). Oncologist 2007;12:991–998.
   PubMed Web of Science ®Google Scholar
• Graham ML. Pegaspargase: a review of clinical studies. Adv Drug Deliv Rev 2003;55:1293–1302.
   PubMed Web of Science ®Google Scholar
• Duval M, Suciu S, Ferster A, . Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer Children's Leukemia Group phase 3 trial. Blood 2002;99:2734–2739.
   PubMed Web of Science ®Google Scholar
• Ettinger LJ, Kurtzberg J, Voute PA, . An open-label, multicenter study of polyethylene glycol-L-asparaginase of the treatment of acute lymphoblastic leukemia. Cancer 1995;75:1176–1181.
   PubMed Web of Science ®Google Scholar
• Sallan SE. Myths and lessons from the adult/pediatric interface in acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2006:128–132.
   PubMedGoogle Scholar
• Advani A, Earl M, Douer D, Rytting M, Bleyer A. Toxicities of intravenous pegasparaginase (Oncaspar) in adults with acute lymphoblastic leukemia. Blood 2007;110(Suppl. 1): Abstract 2811.
   Google Scholar
• Rytting M, Earl M, Douer D, Muriera B, Advani A, Bleyer A. Toxicities in adults with acute lymphoblastic leukemia treated with regimens using pegasparaginase. Blood 2008;112(Suppl. 1): Abstract 1924.
   Google Scholar
• Earl M. Incidence and management of asparaginase-associated adverse events in patients with acute lymphoblastic leukemia. Clin Adv Hemat Oncol 2009;7:600–606.
   PubMedGoogle Scholar
• Rytting M. Peg-asparaginase for acute lymphoblastic leukemia. Expert Opin Biol Ther 2010;27:1–7.
   Google Scholar
• Seibel NL, Steinherz PG, Sather HN, . Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 2008;111:2548–2555.
   PubMed Web of Science ®Google Scholar
• Muller HJ, Loning L, Horn A, . Pegylated asparaginase (OncasparTM) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols. Br J Haematol 2000;110:379–384.
   PubMed Web of Science ®Google Scholar
• Larson RA, Fretzin MH, Dodge RK, Schiffer CA. Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia. Leukemia 1998;12:660–665.
   PubMed Web of Science ®Google Scholar
• Avramis V, Sencer S, Periclou AP, . A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 2002;99:1986–1994.
   PubMed Web of Science ®Google Scholar
• Armstrong JK, Hempel G, Koling S, . Antibody against polyethylene glycol adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer 2007;110:103–111.
   PubMed Web of Science ®Google Scholar
• Panetta JC, Gajjar A, Hijiya N, . Comparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemia. Clin Pharmacol Ther 2009;86:651–658.
   PubMed Web of Science ®Google Scholar
• Strullu M, Corradini N, Audrain M, . Silent hypersensitivity to Escherichia coli asparaginase in children with acute lymphoblastic leukemia. Leuk Lymphoma 2010;51:1464–1472.
   PubMed Web of Science ®Google Scholar
• Zalewska-Szewczyk B, Andrzejewski W, Młynarski W, Jedrychowska-Dańska K, Witas H, Bodalski J. The anti-asparagines antibodies correlate with L-asparagines activity and may affect clinical outcome of childhood acute lymphoblastic leukemia. Leuk Lymphoma 2007;48:931–936.
   PubMed Web of Science ®Google Scholar
• Cheung NK, Chau IY, Coccia PF. Antibody response to Escherichia coli L-asparaginase. Prognostic significance and clinical utility of antibody measurement. Am J Pediatr Hematol Oncol 1986;8: 99–104.
   PubMedGoogle Scholar
• Vieira Pinheiro JP, Muller HJ, Schwabe D, . Drug monitoring of low-dose pegylated asparaginase (OncasparTM) in children with relapse acute lymphoblastic leukaemia. Br J Haematol 2001; 113:115–119.
   PubMed Web of Science ®Google Scholar
• Douer D, Watkins K, Nathwani N, Levine AM, Tiwari PN, Avramis VI. The pharmacokinetics, safety and lack of antibody production from multiple doses of intravenous pegylated asparaginase in adults with newly diagnosed acute lymphoblastic leukemia. Blood 2006;108(Suppl. 1): Abstract 1873.
   Google Scholar
• Douer D, Watkins K, Mark L, . Multiple doses of intravenous pegylated asparaginase with a ‘pediatric-like’ protocol in adults with newly diagnosed acute lymphoblastic leukemia (ALL): toxicity, clinical outcome and low rate of anti asparaginase antibody formation. Blood 2009;114(Suppl. 1): Abstract 3082.
   Google Scholar
• Avramis V, Panosyan EH. Pharmacokinetic/pharmacodynamics relationships of asparaginase formulations: the past, the present and recommendations for the future. Clin Pharmacokin 2005;44:367–393.
   PubMed Web of Science ®Google Scholar
• Yang L, Panetta JC, Cai X, . Asparaginase may influence dexamethasone pharmacokinetics` in acute lymphoblastic leukemia. J Clin Oncol 2008;26:1932–1939.
   PubMed Web of Science ®Google Scholar
• McNeer JL, Nachman JB. The optimal use of steroids in paediatric acute lymphoblastic leukaemia: no easy answers. Br J Haematol 2010;149:638–652.
   PubMed Web of Science ®Google Scholar
• Knoderer HM, Robarge J, Flockhart DA. Predicting asparaginase-associated pancreatitis. Pediatr Blood Cancer 2007;49:634–639.
   PubMed Web of Science ®Google Scholar
• Top PC, Tissing WJ, Kuiper JW, Pieters R, van Eijck CH. L-asparaginase induced severe acute necrotizing pancreatitis successfully treated with percutaneous drainage. Pediatr Blood Cancer 2005;44:95–97.
   PubMed Web of Science ®Google Scholar
• Kearney S, Dahlberg S, Levy D, Voss SD, Sallan SE, Silverman LB. Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis. Pediatr Blood Cancer 2009;53:162–167.
   PubMed Web of Science ®Google Scholar
• Hawkins DS, Park JR, Thomson BG, . Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia. Clin Cancer Res 2004;10:5335–5341.
   PubMed Web of Science ®Google Scholar
• Abshire T, Pollock B, Billett A, . Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood 2000;96:1709–1715.
   PubMed Web of Science ®Google Scholar
• Rizzari C, Citterio M, Zucchetti M, . A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia. Haematologica 2006;91:24–31.
   PubMed Web of Science ®Google Scholar
• Alvarez OA, Zimmerman G. Pegaspargase-induced pancreatitis. Med Pediatr Oncol 2000;34:200–205.
   PubMedGoogle Scholar
• Land VJ, Sutow WW, Fernbach DJ, . Toxicity of l-asparaginase in children with advanced leukemia. Cancer 1972;30:339–347.
   PubMed Web of Science ®Google Scholar
• Garrington T, Bensard D, Ingram JD, Silliman CC. Successful management with octreotide of a child with L-asparaginase induced hemorrhagic pancreatitis. Med Pediatr Oncol 1998;30;106–109.
   PubMedGoogle Scholar
• Suzuki M, Takara O, Sakaguchi S, Fujimara J, Saito M, Shimizu T. Retherapy using L-asparaginase with octreotide in a patient recovering from L-asparginase-induced pancreastitis. Exp Hematol 2008;36: 253–254.
   PubMed Web of Science ®Google Scholar
• Paran H, Neufeld D, Mayo A, . Preliminary report of a prospective randomized study of octreotide in the treatment of severe acute pancreatitis. J Am Coll Surg 1995;181:121–124.
   PubMed Web of Science ®Google Scholar
• Tauber MT, Harris AG, Rochiccioli P. Clinical use of the long acting somatostatin analogue octreotide in pediatrics. Eur J Pediatr 1994:153:304–310.
   PubMed Web of Science ®Google Scholar
• Morimoto A, Imamura T, Ishii R, . Successful management of severe L-asparaginase-associated pancreatitis by continuous regional arterial infusion of protease inhibitor and antibiotic. Cancer 2008;113:1362–1369.
   PubMed Web of Science ®Google Scholar
• Imaizumi H, Kida M, Nishimaki H, . Efficacy of continuous regional arterial infusion of a protease inhibitor and antibiotic for severe acute pancreatitis in patients admitted to an intensive care unit. Pancreas 2004;28:369–373.
   PubMed Web of Science ®Google Scholar
• Taylor CW, Dorr RT, Fanta P, . A phase I and pharmacodynamics evaluation of polyethylene glycol–conjugated L–asparaginase in patients with advanced solid tumors. Cancer Chemother Pharmacol 2001;47:83–88.
   PubMed Web of Science ®Google Scholar
• Whitecar JP Jr, Bodey GP, Hill CS Jr, Samaan NA. Effect of L-asparaginase on carbohydrate metabolism. Metabolism 1970; 19:581–586.
   PubMed Web of Science ®Google Scholar
• Gailani S, Nussbaum A, Onuma T, Freeman A. Diabetes in patients treated with asparaginase. Clin Pharmacol Ther 1971;12: 487–490.
   PubMed Web of Science ®Google Scholar
• Carpentieri U, Balch MT. Hyperglycemia associated with the therapeutic use of L-asparaginase: possible role of insulin receptors. J Pediatr 1978;93:775–778.
   PubMed Web of Science ®Google Scholar
• Khan A, Adachi M, Hill JM. Potentiation of diabetogenic effect of L-asparaginase by prednisolone. Horm Metab Res 1970;2: 275–276.
   PubMedGoogle Scholar
• Lowas S, Marks D, Malempati S. Prevalence of transient hyperglycemia during induction chemotherapy for pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer 2009;52:814–818.
   PubMed Web of Science ®Google Scholar
• Salzer WL, Devidas M, Schuster JJ, . Intensified PEG-l-asparaginase and antimetabolite-based therapy for treatment of higher risk precursor-B acute lymphoblastic leukemia: a report from the Children's Oncology Group. J Pediatr Hematol Oncol 2007;29:369–375.
   PubMed Web of Science ®Google Scholar
• Douer D, Yampolsky H, Cohen LJ, . Pharmacodynamics and safety of intravenous pegasparaginase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood 2007;109:2744–2750.
   PubMed Web of Science ®Google Scholar
• Pui CH, Burghen GA, Bowman WP, Aur RJ. Risk factors for hyperglycemia in children with leukemia receiving L-asparaginase and prednisone. J Pediatr 1981;99:46–50.
   PubMed Web of Science ®Google Scholar
• Howard SC, Pui CH. Endocrine complications in pediatric patients with acute lymphoblastic leukemia. Blood Rev 2002;16: 224–234.
   Web of Science ®Google Scholar
• Cairo MS. Adverse reactions of l-asparaginase. Am J Pediatr Hemat Oncol 1982;4:335–339.
   PubMedGoogle Scholar
• Sahoo S, Hart J. Histopathologic features of l-asparaginase-induced liver disease. Semin Liver Dis 2003;23:295–299.
   PubMed Web of Science ®Google Scholar
• Schein PS, Rakieten N, Gordon BM, Davis RD, Rau DP. The toxicity of Escherichia coli l-asparaginase. Cancer Res 1969;29:426–434.
   PubMed Web of Science ®Google Scholar
• Bodmer M, Sulz M, Stadlmann S, Droll A, Terracciano L, Krähenbühl S. Fatal liver failure in an adult patient with acute lymphoblastic leukemia following treatment with L asparaginase. Digestion 2006;74:28–32.
   PubMed Web of Science ®Google Scholar
• Parsons SK, Skapek SX, Neufeld EJ, . Asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia. Blood 1997;89:1886–1895.
   PubMed Web of Science ®Google Scholar
• Haskell CA, Canellos GJ, Leventhall BJ. L-asparaginase toxicity. Cancer Res 1969;29:974–975.
   PubMed Web of Science ®Google Scholar
• Whitecar JP, Bodey GP, Harris JE, . L-asparaginase. N Engl J Med 1970;282:732–734.
   PubMed Web of Science ®Google Scholar
• Durden DL, Salazar AM, Distusio JA. Kinetic analysis of hepatotoxicity associated with antineoplastic asparaginases. Cancer Res 1983;43:1602–1605.
   PubMed Web of Science ®Google Scholar
• Capizzi RL. Asparaginase-Mtx in combination chemotherapy: schedule-dependent differential effects on normal versus neoplastic cells. Cancer Chemother Rep 1981;65:115–121.
   Google Scholar
• Capizzi RL, Griffin F, Cheng YC, Baily K, Rudnick SA. High dose Ara-C with asparaginase in the treatment of refractory leukemia. Proc Am Assoc Cancer Res 1980;21:148 [Abstract].
   Web of Science ®Google Scholar
• Schwartz S, Morganstern B, Capizzi RL. Schedule-dependent synergy and antagonism between high-dose 1-β-D-arabinofuranosyl cytosine and asparaginase in the L5178Y murine leukemia. Cancer Res 1982;42:2191–2197.
   PubMed Web of Science ®Google Scholar
• Ladas EJ, Kroll DJ, Oberlies NH, . A randomized, controlled, double-blind, pilot study of milk thistle for the treatment of hepatotoxicity in childhood acute lymphoblastic leukemia. Cancer 2010;116:506–513.
   PubMed Web of Science ®Google Scholar
• Hongo T, Okada S, Ohzeki T, . Low plasma levels of hemostatic proteins during the induction phase in children with acute lymphoblastic leukemia: a retrospective study by the JACLS. Japan Association of Childhood Leukemia Study. Pediatr Int 2002;44: 293–299.
   PubMed Web of Science ®Google Scholar
• Andrew M, Brooker L, Mitchell L. Acquired antithrombin III deficiency secondary to asparaginase therapy in childhood acute lymphoblastic leukaemia. Blood Coagul Fibrinolysis 1994;5 (Suppl. 1):S24–S36;discussion S59–S64.
   PubMed Web of Science ®Google Scholar
• Mitchell L, Hoogendoorn H, Giles AR, Vegh P, Andrew M. Increased endogenous thrombin generation in children with acute lymphoblastic leukemia:risk of thrombotic complications in L-asparaginase-induced antithrombin III deficiency. Blood 1994;83:386–391.
   PubMed Web of Science ®Google Scholar
• Bushman JE, Palmieri D, Whinna HC, Church FC. Insight into the mechanism of asparaginase-induced depletion of antithrombin III in treatment of childhood acute lymphoblastic leukemia. Leuk Res 2000;24:559–565.
   PubMed Web of Science ®Google Scholar
• Hernandez-Espinosa D, Minano A, Martinez C, . L-asparaginase-induced antithrombin type I deficiency: implications for conformational diseases. Am J Pathol 2006;169:142–153.
   PubMed Web of Science ®Google Scholar
• Hernandez-Espinosa D, Minano A, Ordonez A, . Dexamethasone induces a heat-stress response that ameliorates the conformational consequences on antithrombin of L-asparaginase treatment. J Thromb Haemost 2009;7:1128–1133.
   PubMed Web of Science ®Google Scholar
• Priest JR, Ramsay NK, Latchaw RE, . Thrombotic and hemorrhagic strokes complicating early therapy for childhood acute lymphoblastic leukemia. Cancer 1980;46:1548–1554.
   PubMed Web of Science ®Google Scholar
• Liebman HA, Wada JK, Patch MJ, McGehee W. Depression of functional and antigenic plasma antithrombin III (AT-III) due to therapy with L-asparaginase. Cancer 1982;50:451–456.
   PubMed Web of Science ®Google Scholar
• Mitchell LG, Halton JM, Vegh PA, . Effect of disease and chemotherapy on hemostasis in children with acute lymphoid leukemia. Am J Pediatr Hematol Oncol 1994;16:120–126.
   PubMedGoogle Scholar
• Jonas Kimchi T, Lee SK, Agid R, Shroff M, Ter Brugge KG. Cerebral sinovenous thrombosis in children. Neuroimaging Clin N Am 2007;17:239–244.
   PubMed Web of Science ®Google Scholar
• Caruso V, Iacoviello L, Di Castelnuovo A, . Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood 2006;108:2216–2222.
   PubMed Web of Science ®Google Scholar
• Payne JH, Vora AJ. Thrombosis and acute lymphoblastic leukaemia. Br J Haematol 2007;138:430–445.
   PubMed Web of Science ®Google Scholar
• Nowak-Gottl U, Kenet G, Mitchell LG. Thrombosis in childhood acute lymphoblastic leukaemia: epidemiology, aetiology, diagnosis, prevention and treatment. Best Pract Res Clin Haematol 2009;22:103–114.
   PubMed Web of Science ®Google Scholar
• Kieslich M, Porto L, Lanfermann H, Jacobi G, Schwabe D, Bohles H. Cerebrovascular complications of L-asparaginase in the therapy of acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2003;25:484–487.
   PubMed Web of Science ®Google Scholar
• Qureshi A, Mitchell C, Richards S, Ajay Vora A, Goulden N. Asparaginase-related venous thrombosis in UKALL 2003 - re-exposure to asparaginase is feasible and safe. Br J Haematol 2010;149: 410–413.
   PubMed Web of Science ®Google Scholar
• Grace RF, Dahlberg SE, Neuberg D, . The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haematol 2011;152:452–459.
   PubMed Web of Science ®Google Scholar
• Caruso V, Iacoviello L, Di Castelnuovo A, Storti S, Mariani G, de Gaetano G, Donati MB. Thromboticcomplicationsinchildhoodacutelymphoblasticleukemia:ameta-analysisof17prospectivestudiescomprising1752pediatricpatients. Blood 2006; 108:2216–2222.
   PubMed Web of Science ®Google Scholar
• Elliott MA, Wolf RC, Hook CC, . Thromboembolism in adults with acute lymphoblastic leukemia during induction with L-asparaginase-containing multi-agent regimens: incidence, risk factors, and possible role of antithrombin. Leuk Lymphoma 2004;45:1545–1549.
   PubMed Web of Science ®Google Scholar
• Hunault-Berger M, Chevallier P, Delain M, . Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study. Haematologica 2008;93:1488–1494.
   PubMed Web of Science ®Google Scholar
• Caruso V, Iacoviello L, Di Castelnuovo A, Storti S, Donati MB. Venous thrombotic complications in adults undergoing induction treatment for acute lymphoblastic leukemia: results from a meta-analysis. J Thromb Haemost 2007;5:621–623.
   PubMed Web of Science ®Google Scholar
• Gugliotta L, Mazzucconi MG, Leone G, . Incidence of thrombotic complications in adult patients with acute lymphoblastic leukaemia receiving L-asparaginase during induction therapy: a retrospective study. The GIMEMA Group. Eur J Haematol 1992;49:63–66.
   PubMed Web of Science ®Google Scholar
• Abbott LS, Deevska M, Fernandez CV, . The impact of prophylactic fresh-frozen plasma and cryoprecipitate on the incidence of central nervous system thrombosis and hemorrhage in children with acute lymphoblastic leukemia receiving asparaginase. Blood 2009;114:5146–5151.
   PubMed Web of Science ®Google Scholar
• Appel IM, Hop WC, van Kessel-Bakvis C, Stigter R, Pieters R. L-Asparaginase and the effect of age on coagulation and fibrinolysis in childhood acute lymphoblastic leukemia. Thromb Haemost 2008;100:330–337.
   PubMed Web of Science ®Google Scholar
• Nowak-Gottl U, Ahlke E, Fleischhack G, . Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration. Blood 2003;101:2529–2533.
   PubMed Web of Science ®Google Scholar
• Nowak-Gottl U, Wermes C, Junker R, . Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors. Blood 1999;93:1595–1599.
   PubMed Web of Science ®Google Scholar
• Mitchell LG, Andrew M, Hanna K, . A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study. Cancer 2003;97:508–516.
   PubMed Web of Science ®Google Scholar
• Naina HV, Harris S, Patnaik MM. Treating childhood leukemia without cranial irradiation. N Engl J Med 2009;361:1310–1311; author reply 1311–1312.
   PubMed Web of Science ®Google Scholar
• Meister B, Kropshofer G, Klein-Franke A, Strasak AM, Hager J, Streif W. Comparison of low-molecular-weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2008;50: 298–303.
   PubMed Web of Science ®Google Scholar
• Korte W, Greiner J. PARKAA paves the way. Thromb Haemost 2003;90:163–164.
   PubMed Web of Science ®Google Scholar
• Jaing TH, Lin JL, Lin YP, Yang SH, Lin JJ, Hsia SH. Hyperammonemic encephalopathy after induction chemotherapy for acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2009; 31: 955–956.
   PubMed Web of Science ®Google Scholar
• Miyazawa Y, Irisawa H, Matsushima T, . Reversible posterior leukoencephalopathy syndrome probably caused by L-asparaginase. Rinsho Ketsueki 2006;47:531–535.
   PubMedGoogle Scholar
• Rathi B, Azad RK, Vasudha N, Hissaria P, Sawlani V, Gupta RK. L asparaginase-induced reversible posterior leukoencephalopathy syndrome in a child with acute lymphoblastic leukemia. Pediatr Neurosurg 2002;37:203–205.
   PubMed Web of Science ®Google Scholar
• Winick NJ, Bowman WP, Kamen BA, . Unexpected acute neurologic toxicity in the treatment of children with acute lymphoblastic leukemia. J Natl Cancer Inst 1992;84:252–256.
   PubMed Web of Science ®Google Scholar
• Silverman LB, Supko JG, Stevenson KE, . Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia. Blood 2010;115:1351–1353.
   PubMed Web of Science ®Google Scholar
• Peters BG, Goeckner BJ, Ponzillo JJ, Velasquez WS, Wilson AL. Pegaspargase versus L-asparaginase in adult ALL: a pharmacoeconomic assessment. Formulary 1995;30:388–393.
   PubMed Web of Science ®Google Scholar
• van den Berg H. Asparaginase revisited. Leuk Lymphoma 2011; 52:168–178.
   PubMed Web of Science ®Google Scholar
• Benezra D, Pitaro R, Birkenfeld U, Hochman A. Reversal of the immunosuppressive effect of l-asparaginase by l-glutamine. Nat New Biol 1972;236:80–82.
   PubMedGoogle Scholar
• Uren JR, Handschumacher RE. Enzyme therapy. Becker FF. Cancer: a comprehensive treatise, Vol. 5. New York: Plenum Publishing; 1977. 457–487.
   Google Scholar
• Woods JS, Handschumacher RE. Hepatic homeostasis of plasma l-asparagine. Am J Physiol 1971;221:1785–1790.
   PubMed Web of Science ®Google Scholar
• Miller HK, Salser JS, Balis ME. Amino acid levels following l-asparagine amino hydrolase (EC 3.5.1.1) therapy. Cancer Res 1969;29:183–187.
   PubMed Web of Science ®Google Scholar
• Rytting M, Thomas D, Franklin A, . Young adults with acute lymphoblastic leukemia (ALL) treated with adapted augmented Berlin-Frankfurt-Munster (ABFM) therapy. Blood 2008;112(Suppl. 1): Abstract 3957.
   Google Scholar